MNKD

$3.935.36%0.20

Nachbörslich: 3.90-0.03 -0.76%

Mannkind Corp (MNKD)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$3.73

Offen:

$3.86

24-Stunden-Volumen:

3,818,154

Relatives Volumen:

1.27

Marktkapitalisierung:

$1.26B

Einnahmen:

$360.78M

Nettoeinkommen (Verlust:

-$23.91M

KGV:

EPS:

-$0.0781

Netto-Cashflow:

$13.07M

1W Leistung:

+14.58%

1M Leistung:

+3.42%

6M Leistung:

+39.86%

1Y Leistung:

-28.28%

1-Tages-Spanne:

$3.80$4.05

1-Wochen-Bereich:

$3.45$4.05

52-Wochen-Spanne:

$2.23$6.51

Mannkind Corp Aktie (MNKD) Unternehmensprofil

Firmenname

Mannkind Corp

Sektor

Healthcare

Branche

Biotechnology

Telefon

818-661-5000

Adresse

1 CASPER STREET, DANBURY, CA, USA

Mitarbeiter

592

@MannKindCorp

Nächster Verdiensttermin

2026-11-05

Neueste SEC-Einreichungen

SEC

MNKD-Diskussionen auf X

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Mannkind Corp Aktie (MNKD) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-10-19	Eingeleitet	Chardan Capital Markets	Buy
2026-02-27	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-11-24	Eingeleitet	Truist	Buy
2025-11-13	Eingeleitet	Leerink Partners	Outperform
2025-10-20	Eingeleitet	Wells Fargo	Overweight
2025-10-10	Eingeleitet	Leerink Partners	Outperform
2025-07-16	Resumed	H.C. Wainwright	Buy
2025-04-10	Eingeleitet	Mizuho	Outperform
2025-02-10	Eingeleitet	Wedbush	Outperform
2024-12-20	Eingeleitet	Wells Fargo	Overweight
2024-12-19	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2024-09-09	Resumed	Leerink Partners	Outperform
2024-06-13	Eingeleitet	Rodman & Renshaw	Buy
2023-10-10	Eingeleitet	Wedbush	Outperform
2021-05-14	Eingeleitet	RBC Capital Mkts	Sector Perform
2019-12-24	Eingeleitet	Oppenheimer	Outperform
2019-10-25	Eingeleitet	Cantor Fitzgerald	Overweight
2019-05-14	Eingeleitet	BTIG Research	Buy
2019-03-04	Eingeleitet	SVB Leerink	Outperform
2019-02-22	Eingeleitet	SVB Leerink	Outperform
2018-02-28	Herabstufung	Maxim Group	Hold → Sell
2017-11-01	Herabstufung	Maxim Group	Buy → Hold
2017-10-10	Eingeleitet	H.C. Wainwright	Buy
2017-10-06	Bestätigt	Maxim Group	Buy
2017-08-11	Eingeleitet	Maxim Group	Buy
2016-05-10	Bestätigt	Piper Jaffray	Underweight
2016-05-10	Bestätigt	RBC Capital Mkts	Underperform
2016-01-06	Bestätigt	Piper Jaffray	Underweight
2016-01-06	Bestätigt	RBC Capital Mkts	Underperform
2015-11-04	Herabstufung	RBC Capital Mkts	Outperform → Underperform
2015-09-09	Herabstufung	Piper Jaffray	Neutral → Underweight
2015-08-03	Bestätigt	RBC Capital Mkts	Outperform
2015-05-11	Herabstufung	JP Morgan	Neutral → Underweight
2015-05-11	Bestätigt	MLV & Co	Hold
2015-04-16	Bestätigt	RBC Capital Mkts	Outperform

Finanzdaten der Mannkind Corp-Aktie (MNKD)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	348.97	285.50	198.96	99.77	75.44
Cost of revenue USD (M)	26.80	17.43	20.86	16.00	16.83
Gross profit USD (M)	-	-	178.10	83.77	58.61
Operating expenses USD (M)	87.96	76.60	62.77	57.50	105.63
Operating income USD (M)	38.80	72.59	8.68	-64.11	-47.02
Income before tax USD (M)	1.41	30.52	-10.38	-87.40	-80.93
Income tax expense USD (M)	-4.46	2.93	1.56	0.00	0.00
Net income USD (M)	5.86	27.59	-11.94	-87.40	-80.93
Basic EPS USD/shares	0.02	0.10	-0.04	-0.34	-
Diluted EPS USD/shares	0.02	0.10	-0.04	-0.34	-
Basic weighted shares shares (M)	305.64	274.42	267.01	257.09	-
Diluted weighted shares shares (M)	314.11	283.84	267.01	257.09	-
Selling, general and administrative USD (M)	144.14	94.33	-	-	77.42

Mannkind Corp-Aktie (MNKD) Insiderhandel

STEVEN BINDERSep 25 '26
Director
Transaktion
Proposed Sale
Kosten
$3.29
#Aktien
39,051
Wert ($)
128,478
#Aktien Gesamt
0
Binder Steven B.Sep 25 '26
Director
Transaktion
Sale
Kosten
$3.29
#Aktien
39,051
Wert ($)
128,478
#Aktien Gesamt
713,258
STEVEN BINDERSep 10 '26
Director
Transaktion
Proposed Sale
Kosten
$3.94
#Aktien
33,558
Wert ($)
132,219
#Aktien Gesamt
0
Binder Steven B.Sep 10 '26
Director
Transaktion
Sale
Kosten
$3.81
#Aktien
33,558
Wert ($)
127,856
#Aktien Gesamt
752,309
STEVEN BINDERAug 07 '26
Director
Transaktion
Proposed Sale
Kosten
$3.89
#Aktien
39,051
Wert ($)
151,908
#Aktien Gesamt
0
Binder Steven B.Aug 07 '26
Director
Transaktion
Sale
Kosten
$4.06
#Aktien
39,051
Wert ($)
158,547
#Aktien Gesamt
785,867
DAVID THOMSONJul 17 '26
Officer
Transaktion
Proposed Sale
Kosten
$4.04
#Aktien
24,109
Wert ($)
97,400
#Aktien Gesamt
0
STEVEN BINDERJul 17 '26
Director
Transaktion
Proposed Sale
Kosten
$4.04
#Aktien
52,485
Wert ($)
212,039
#Aktien Gesamt
0
Thomson DavidJul 17 '26
EVP Genl Counsel & Secretary
Transaktion
Sale
Kosten
$4.05
#Aktien
24,109
Wert ($)
97,641
#Aktien Gesamt
797,554
Binder Steven B.Jul 17 '26
Director
Transaktion
Sale
Kosten
$4.06
#Aktien
52,485
Wert ($)
213,089
#Aktien Gesamt
824,918

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
STEVEN BINDER	Director	Sep 25 '26	Proposed Sale	$3.29	39,051	128,478	0
Binder Steven B.	Director	Sep 25 '26	Sale	$3.29	39,051	128,478	713,258
STEVEN BINDER	Director	Sep 10 '26	Proposed Sale	$3.94	33,558	132,219	0
Binder Steven B.	Director	Sep 10 '26	Sale	$3.81	33,558	127,856	752,309
STEVEN BINDER	Director	Aug 07 '26	Proposed Sale	$3.89	39,051	151,908	0
Binder Steven B.	Director	Aug 07 '26	Sale	$4.06	39,051	158,547	785,867
DAVID THOMSON	Officer	Jul 17 '26	Proposed Sale	$4.04	24,109	97,400	0
STEVEN BINDER	Director	Jul 17 '26	Proposed Sale	$4.04	52,485	212,039	0
Thomson David	EVP Genl Counsel & Secretary	Jul 17 '26	Sale	$4.05	24,109	97,641	797,554
Binder Steven B.	Director	Jul 17 '26	Sale	$4.06	52,485	213,089	824,918

Mannkind Corp Aktie (MNKD) Neueste Nachrichten

Nov 03, 2026

MannKind’s IPF inhalation medical treatment passes Phase 1b - Westfair Communications

Nov 03, 2026

Oct 30, 2026

MannKind Corporation (NNFN.F) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Oct 30, 2026

MannKind's Furosix Ramp And Pediatric Afrezza Uptake Face First Real Test After Catalyst Sweep - Finviz

Oct 30, 2026

Oct 29, 2026

MannKind stock sets November 5 date for third-quarter results - ad-hoc-news.de

Oct 29, 2026

MannKind Corporation (MNKD) Interactive Stock Chart - Yahoo Finance - Yahoo! Finance Canada

Oct 29, 2026

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026 - The Manila Times

Oct 29, 2026

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026 - The Manila Times

Oct 29, 2026

Oct 23, 2026

MannKind Corporation Estimates – NASDAQ:MNKD - TradingView

Oct 23, 2026

Oct 22, 2026

Price to earnings forward of MannKind Corporation – SWB:NNFN - TradingView

Oct 22, 2026

Oct 20, 2026

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth - Yahoo Finance

Oct 20, 2026

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth - TradingView

Oct 20, 2026

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth - TradingView

Oct 20, 2026

Chardan starts coverage of MannKind stock with a USD 10.00 target - AD HOC NEWS

Oct 20, 2026

MNKD Reiterated by Cantor Fitzgerald -- Price Target Maintained at $8.00 - GuruFocus

Oct 20, 2026

Oct 19, 2026

Learn Why The Bull Case For MannKind Stock Could Change Following Outpatient Diuretic Data - Yahoo Finance

Oct 19, 2026

MNKD: IPF pipeline advances as ReadyFlow and TYVASO DPI support growth and diversification - TradingView

Oct 19, 2026

Chardan initiates MannKind stock coverage with buy rating on pipeline - Investing.com

Oct 19, 2026

This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Oct 19, 2026

MNKD Initiates Coverage On Chardan Capital -- Price Target Annou - GuruFocus

Oct 19, 2026

Oct 15, 2026

Does MannKind (MNKD) Have a Differentiated Cardiorenal Strategy or Just Incremental Delivery Innovation? - Yahoo Finance

Oct 15, 2026

MannKind stock rises 4.54 percent on Nasdaq at EUR 2.81 - ad-hoc-news.de

Oct 15, 2026

Oct 14, 2026

MannKind CEO to join panel on chronic respirato... - Pluang

Oct 14, 2026

MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire Inc.

Oct 14, 2026

A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein. - Stock Titan

Oct 09, 2026

New data supports Furoscix ReadyFlow autoinject... - Pluang

Oct 09, 2026

MannKind Presents New Data Showing Furoscix ReadyFlow Delivers IV-Equivalent Diuresis Across Injection Sites at HFSA 2026 - Quiver Quantitative

Oct 09, 2026

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) - GlobeNewswire Inc.

Oct 09, 2026

Oct 07, 2026

MNKD Maintains Buy Rating -- Price Target Lowered to $5.00 by Truist Securities - GuruFocus

Oct 07, 2026

Oct 05, 2026

MannKind stock weighs 43 percent revenue growth against losses - AD HOC NEWS

Oct 05, 2026

Sep 30, 2026

Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquid - GuruFocus

Sep 30, 2026

MNKD Stock Draws Trader Focus On Rose Pharma GLP-1 Deal - StocksToTrade

Sep 30, 2026

MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com

Sep 30, 2026

MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com

Sep 30, 2026

Sep 29, 2026

Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com South Africa

Sep 29, 2026

Sep 28, 2026

Director Steven Binder Sells 39,051 Shares of MannKind Corp (MNK - GuruFocus

Sep 28, 2026

Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Nigeria

Sep 28, 2026

Form 4 MannKind Corp For: 28 September By Investing.com - Investing.com Nigeria

Sep 28, 2026

Steven Binder sells $128,477 of MannKind (MNKD) stock - Investing.com

Sep 28, 2026

Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Canada

Sep 28, 2026

Sep 25, 2026

Form 144 MannKind Corporation For: 25 September - Investing.com India

Sep 25, 2026

Form 144 MannKind Corporation For: 25 September By Investing.com - Investing.com Canada

Sep 25, 2026

Shares valued at $128,478 are proposed for sale by MannKind (MNKD) director Steven Binder. - Stock Titan

Sep 25, 2026

Sep 23, 2026

Danbury Company Reports Positive Results In Lung Disease Drug Trial - Patch

Sep 23, 2026

MannKind Corporation (MNKD) Options Chain - Yahoo Finance - Yahoo! Finance Canada

Sep 23, 2026

Sep 22, 2026

MannKind Corporation (MNKD) Stock Analysis: Exploring a 127.68% Potential Upside in the Biotech Space - DirectorsTalk Interviews

Sep 22, 2026

Sep 19, 2026

MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost - Stocktwits

Sep 19, 2026

Sep 18, 2026

Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us

Sep 18, 2026

Ähnlich wie MNKD

Mannkind Corp (MNKD)

Mannkind Corp Aktie (MNKD) Unternehmensprofil

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Mannkind Corp Aktie (MNKD) Hochstufungen & Herabstufungen

Finanzdaten der Mannkind Corp-Aktie (MNKD)

Mannkind Corp-Aktie (MNKD) Insiderhandel

Mannkind Corp Aktie (MNKD) Neueste Nachrichten

MannKind’s IPF inhalation medical treatment passes Phase 1b - Westfair Communications

MannKind Corporation (NNFN.F) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

MannKind's Furosix Ramp And Pediatric Afrezza Uptake Face First Real Test After Catalyst Sweep - Finviz

MannKind stock sets November 5 date for third-quarter results - ad-hoc-news.de

MannKind Corporation (MNKD) Interactive Stock Chart - Yahoo Finance - Yahoo! Finance Canada

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026 - The Manila Times

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026 - The Manila Times

MannKind Corporation Estimates – NASDAQ:MNKD - TradingView

Price to earnings forward of MannKind Corporation – SWB:NNFN - TradingView

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth - Yahoo Finance

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth - TradingView

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth - TradingView

Chardan starts coverage of MannKind stock with a USD 10.00 target - AD HOC NEWS

MNKD Reiterated by Cantor Fitzgerald -- Price Target Maintained at $8.00 - GuruFocus

Learn Why The Bull Case For MannKind Stock Could Change Following Outpatient Diuretic Data - Yahoo Finance

MNKD: IPF pipeline advances as ReadyFlow and TYVASO DPI support growth and diversification - TradingView

Chardan initiates MannKind stock coverage with buy rating on pipeline - Investing.com

This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

MNKD Initiates Coverage On Chardan Capital -- Price Target Annou - GuruFocus

Does MannKind (MNKD) Have a Differentiated Cardiorenal Strategy or Just Incremental Delivery Innovation? - Yahoo Finance

MannKind stock rises 4.54 percent on Nasdaq at EUR 2.81 - ad-hoc-news.de

MannKind CEO to join panel on chronic respirato... - Pluang

MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire Inc.

MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire

MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire

MannKind to Participate in the Chardan Healthcare Conference - Yahoo Finance

A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein. - Stock Titan

New data supports Furoscix ReadyFlow autoinject... - Pluang

MannKind Presents New Data Showing Furoscix ReadyFlow Delivers IV-Equivalent Diuresis Across Injection Sites at HFSA 2026 - Quiver Quantitative

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) - GlobeNewswire Inc.

MNKD Maintains Buy Rating -- Price Target Lowered to $5.00 by Truist Securities - GuruFocus

MannKind stock weighs 43 percent revenue growth against losses - AD HOC NEWS

Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquid - GuruFocus

MNKD Stock Draws Trader Focus On Rose Pharma GLP-1 Deal - StocksToTrade

MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com

MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com

Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com South Africa

Director Steven Binder Sells 39,051 Shares of MannKind Corp (MNK - GuruFocus

Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Nigeria

Form 4 MannKind Corp For: 28 September By Investing.com - Investing.com Nigeria

Steven Binder sells $128,477 of MannKind (MNKD) stock - Investing.com

Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Canada

Form 144 MannKind Corporation For: 25 September - Investing.com India

Form 144 MannKind Corporation For: 25 September By Investing.com - Investing.com Canada

Shares valued at $128,478 are proposed for sale by MannKind (MNKD) director Steven Binder. - Stock Titan

Danbury Company Reports Positive Results In Lung Disease Drug Trial - Patch

MannKind Corporation (MNKD) Options Chain - Yahoo Finance - Yahoo! Finance Canada

MannKind Corporation (MNKD) Stock Analysis: Exploring a 127.68% Potential Upside in the Biotech Space - DirectorsTalk Interviews

MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost - Stocktwits

Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us

Ähnlich wie MNKD